BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G; Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110:1376-1384. [PMID: 17634949 DOI: 10.1002/cncr.22904] [Cited by in Crossref: 265] [Cited by in F6Publishing: 216] [Article Influence: 18.9] [Reference Citation Analysis]
Number Citing Articles
1 Sprangers B, Sandhu G, Rosner MH, Tesarova P, Stadler WM, Malyszko J. Drug dosing in cancer patients with decreased kidney function: A practical approach. Cancer Treat Rev 2021;93:102139. [PMID: 33370636 DOI: 10.1016/j.ctrv.2020.102139] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Izzedine H, Négrier S, Neuzillet Y, Zini L. Gestion des effets secondaires des thérapies ciblées dans le cancer du rein : effets secondaires néphrologiques. Bulletin du Cancer 2011;98:S7-S18. [DOI: 10.1684/bdc.2011.1449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Russo P, Szczech LA, Torres GS, Swartz MD. Patient and caregiver knowledge and utilization of partial versus radical nephrectomy: results of a national kidney foundation survey to assess educational needs of kidney cancer patients and caregivers. Am J Kidney Dis 2013;61:939-46. [PMID: 23523238 DOI: 10.1053/j.ajkd.2013.01.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
4 Seethapathy H, Street S, Strohbehn I, Lee M, Zhao SH, Rusibamayila N, Chute DF, Gao X, Michaelson MD, Rahma OE, Choueiri TK, McGregor B, Sonpavde G, Salabao C, Kaymakcalan MD, Wei X, Gupta S, Motwani S, Leaf DE, Reynolds KL, Sise ME. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. Eur J Cancer 2021;157:50-8. [PMID: 34482189 DOI: 10.1016/j.ejca.2021.07.031] [Reference Citation Analysis]
5 Campbell GA, Hu D, Okusa MD. Acute kidney injury in the cancer patient. Adv Chronic Kidney Dis 2014;21:64-71. [PMID: 24359988 DOI: 10.1053/j.ackd.2013.08.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
6 Scotté F, Rey JB, Launay-vacher V. Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads. Support Care Cancer 2012;20:3033-42. [DOI: 10.1007/s00520-012-1590-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
7 Heiken JP. Contrast safety in the cancer patient: preventing contrast-induced nephropathy. Cancer Imaging 2008;8 Spec No A:S124-7. [PMID: 18852085 DOI: 10.1102/1470-7330.2008.9018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
8 Khambati HK, Choueiri TK, Kollmannsberger CK, North S, Bjarnason GA, Vaishampayan UN, Wood L, Knox JJ, Tan MH, MacKenzie MJ, Donskov F, Rini BI, Heng DY; International mRCC Database Consortium. Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. Clin Genitourin Cancer 2014;12:354-8. [PMID: 24819320 DOI: 10.1016/j.clgc.2014.02.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
9 Meghani SH, Kang Y, Chittams J, McMenamin E, Mao JJ, Fudin J. African Americans with cancer pain are more likely to receive an analgesic with toxic metabolite despite clinical risks: a mediation analysis study. J Clin Oncol. 2014;32:2773-2779. [PMID: 25049323 DOI: 10.1200/jco.2013.54.7992] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
10 Woodruff S, Feugère G, Abreu P, Heissler J, Ruiz MT, Jen F. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. J Thromb Thrombolysis 2016;42:494-504. [PMID: 27344439 DOI: 10.1007/s11239-016-1386-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
11 Ubukata M, Hara M, Nishizawa Y, Fujii T, Nitta K, Ohta A. Prevalence and mortality of chronic kidney disease in lymphoma patients: A large retrospective cohort study. Medicine (Baltimore) 2018;97:e9615. [PMID: 29480866 DOI: 10.1097/MD.0000000000009615] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
12 Bauersachs RM. LMWH in cancer patients with renal impairment – better than warfarin? Thrombosis Research 2016;140:S160-4. [DOI: 10.1016/s0049-3848(16)30116-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sande TA, Laird BJA, Fallon MT. The use of opioids in cancer patients with renal impairment—a systematic review. Support Care Cancer 2017;25:661-75. [DOI: 10.1007/s00520-016-3447-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
14 Matzdorff AC, Green D. Management of venous thromboembolism in cancer patients. Reviews in Vascular Medicine 2014;2:24-36. [DOI: 10.1016/j.rvm.2013.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
15 Bezerra ED, Othus M, Shawn C, Percival ME, Gardner K, Walter RB, Becker PS, Hendrie PC, Estey EH. Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 2019;19:e633-5. [PMID: 31648955 DOI: 10.1016/j.clml.2019.06.014] [Reference Citation Analysis]
16 Cosmai L, Porta C, Perazella MA, Launay-vacher V, Rosner MH, Jhaveri KD, Floris M, Pani A, Teuma C, Szczylik CA, Gallieni M. Opening an onconephrology clinic: recommendations and basic requirements. Nephrology Dialysis Transplantation 2018;33:1503-10. [DOI: 10.1093/ndt/gfy188] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
17 Kelly RJ, Billemont B, Rixe O. Renal toxicity of targeted therapies. Targ Oncol 2009;4:121-33. [DOI: 10.1007/s11523-009-0109-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
18 Arellano J, Hernandez RK, Wade SW, Chen K, Pirolli M, Quach D, Quigley J, Liede A, Shahinian VB. Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States. Cancer Med 2015;4:713-20. [PMID: 25663171 DOI: 10.1002/cam4.403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
19 Talreja DB. Importance of antiresorptive therapies for patients with bone metastases from solid tumors. Cancer Manag Res 2012;4:287-97. [PMID: 23049278 DOI: 10.2147/CMAR.S33983] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
20 Bredt LC, Peres LAB. Risk factors for acute kidney injury after partial hepatectomy. World J Hepatol 2017; 9(18): 815-822 [PMID: 28706580 DOI: 10.4254/wjh.v9.i18.815] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
21 Crimmin J, Fulop T, Battisti NML. Biological aspects of aging that influence response to anticancer treatments. Curr Opin Support Palliat Care 2021;15:29-38. [PMID: 33399393 DOI: 10.1097/SPC.0000000000000536] [Reference Citation Analysis]
22 Launay-vacher V, Spano J, Janus N, Gligorov J, Ray-coquard I, Oudard S, Pourrat X, Morere J, Beuzeboc P, Deray G. Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA study. Critical Reviews in Oncology/Hematology 2009;70:124-33. [DOI: 10.1016/j.critrevonc.2008.09.012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
23 Florescu C, Thariat J. Local ablative treatments of oligometastases from head and neck carcinomas. Crit Rev Oncol Hematol 2014;91:47-63. [PMID: 24556572 DOI: 10.1016/j.critrevonc.2014.01.004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
24 Bienholz A, Kribben A. [Acute kidney injury : A clinical syndrome]. Internist (Berl) 2016;57:983-93. [PMID: 27654909 DOI: 10.1007/s00108-016-0138-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
25 Forde PM, Bonomi P, Shaw A, Blumenthal GM, Ferris A, Patel C, Melemed A, Basu Roy U, Ramamoorthy A, Liu Q, Burns T, Gainor JF, Lovly C, Piotrowska Z, Lehman J, Selig W. Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. Clin Lung Cancer 2020;21:295-307. [PMID: 32201247 DOI: 10.1016/j.cllc.2020.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Péron J, Neven A, Collette L, Launay-Vacher V, Sprangers B, Marreaud S. Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials. Nephrol Dial Transplant 2020:gfaa049. [PMID: 32337562 DOI: 10.1093/ndt/gfaa049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Jia W, Wang C, Cheng Y. Decreased Preoperative Estimated Glomerular Filtration Rate Was Related With Poor Prognosis of NSCLC Patients. Technol Cancer Res Treat 2020;19:1533033820952355. [PMID: 32815459 DOI: 10.1177/1533033820952355] [Reference Citation Analysis]
28 Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. J Am Coll Cardiol 2019;73:1336-49. [PMID: 30898209 DOI: 10.1016/j.jacc.2019.01.017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 43.0] [Reference Citation Analysis]
29 Jones M, Denieffe S, Griffin C, Tinago W, Fitzgibbon MC. Evaluation of cystatin C in malignancy and comparability of estimates of GFR in oncology patients. Pract Lab Med 2017;8:95-104. [PMID: 28856234 DOI: 10.1016/j.plabm.2017.05.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
30 Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32. [PMID: 21343556 DOI: 10.1200/JCO.2010.31.3304] [Cited by in Crossref: 773] [Cited by in F6Publishing: 273] [Article Influence: 77.3] [Reference Citation Analysis]
31 Yang Y, Li HY, Zhou Q, Peng ZW, An X, Li W, Xiong LP, Yu XQ, Jiang WQ, Mao HP. Renal Function and All-Cause Mortality Risk Among Cancer Patients. Medicine (Baltimore) 2016;95:e3728. [PMID: 27196494 DOI: 10.1097/MD.0000000000003728] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
32 Deng B, Lin Y, Chen Y, Ma S, Cai Q, Wang W, Li B, Liu T, Zhou P, He R, Ding F. Plasmacytoid dendritic cells promote acute kidney injury by producing interferon-α. Cell Mol Immunol 2021;18:219-29. [PMID: 31900458 DOI: 10.1038/s41423-019-0343-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Laporte S, Bertoletti L, Romera A, Mismetti P, Pérez de Llano LA, Meyer G. Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: A meta-analysis of 5 randomized trials in non-cancer and cancer patients. Thrombosis Research 2012;130:853-8. [DOI: 10.1016/j.thromres.2012.08.290] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
34 Moon HH, Seo KW, Yoon KY, Shin YM, Choi KH, Lee SH. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol 2011; 17(30): 3510-3517 [PMID: 21941418 DOI: 10.3748/wjg.v17.i30.3510] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
35 Terrenato I, Sperati F, Musicco F, Pozzi AF, di Turi A, Caterino M, de Lutio di Castelguidone E, Setola SV, Bellomi M, Neumaier CE, Conti L, Cigliana G, Merola R, Antenucci A, Orlandi G, Giordano A, Barba M, Canitano S. Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. J Cell Physiol 2018;233:2572-80. [PMID: 28777459 DOI: 10.1002/jcp.26132] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
36 Losanno T, Gridelli C. Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. Expert Opin Drug Saf 2016;15:837-51. [PMID: 27007279 DOI: 10.1517/14740338.2016.1170116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
37 Béchade C, Dejardin O, Bara S, Bouvier V, Guizard AV, De Mil R, Troussard X, Lobbedez T, Launoy G. Incidence and characteristics of chronic renal replacement therapy in patients with cancer: data from kidney and cancer registries in Basse-Normandie. J Nephrol 2018;31:111-8. [PMID: 27815918 DOI: 10.1007/s40620-016-0356-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
38 Zimmer-rapuch S, Lheureux S, Brocard F, Janus N, Launay-vacher V, Ray-coquard I. Gestion des agents anticancéreux chez les insuffisants rénaux. Bulletin du Cancer 2012;99:323-31. [DOI: 10.1684/bdc.2011.1489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
39 Béchade C, Dejardin O, Bara S, Bouvier V, Guizard AV, De Mil R, Troussard X, Launoy G, Lobbedez T. Survival of patients with cancer starting chronic dialysis: Data from kidney and cancer registries in lower Normandy. Nephrology (Carlton) 2018;23:1125-30. [PMID: 28633195 DOI: 10.1111/nep.13091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 Cosmai L, Porta C, Gallieni M, Perazella MA. Onco-nephrology: a decalogue: Table 1. Nephrol Dial Transplant 2016;31:515-9. [DOI: 10.1093/ndt/gfv320] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 7.2] [Reference Citation Analysis]
41 Sprangers B, Jhaveri KD, Perazella MA. Improving Cancer Care for Patients With Chronic Kidney Disease. JCO 2020;38:188-92. [DOI: 10.1200/jco.19.02138] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
42 Rolvink J, Gerards AE, Kater AP, Swart EL, Becker ML. The effect of a Clinical Decision Support System on the frequency of dose adjustments of anticancer drugs in case of renal or hepatic dysfunction. J Oncol Pharm Pract 2021;:10781552211019453. [PMID: 34111993 DOI: 10.1177/10781552211019453] [Reference Citation Analysis]
43 de Francisco A, Fernandez E, Cruz J, Casas M, Gómez-gerique J, León A, Cava F, Bedini J, Enguix A, Ripoll E, Borque L, Fernandez A, Arias M. Under-recognized renal insufficiency in hospitalized patients: Implications for care. European Journal of Internal Medicine 2010;21:327-32. [DOI: 10.1016/j.ejim.2010.04.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
44 Inoue N, Watanabe H, Okamura K, Kondo S, Kagami S. Are the equations for the creatinine-based estimated glomerular filtration rate applicable to the evaluation of renal function in Japanese children and adult patients receiving chemotherapy? Clin Exp Nephrol 2015;19:298-308. [PMID: 24792810 DOI: 10.1007/s10157-014-0976-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
45 Russo G, Cioffi G, Di Lenarda A, Tuccia F, Bovelli D, Di Tano G, Alunni G, Gori S, Faggiano P, Tarantini L. Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern Emerg Med 2012;7:439-46. [PMID: 22714882 DOI: 10.1007/s11739-012-0794-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
46 Abdullah SM, Fatma S, Rabbani G, Ashraf JM. A spectroscopic and molecular docking approach on the binding of tinzaparin sodium with human serum albumin. Journal of Molecular Structure 2017;1127:283-8. [DOI: 10.1016/j.molstruc.2016.07.108] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
47 Patel HK, Khorana AA. Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid. Curr Oncol Rep 2019;21:18. [PMID: 30715628 DOI: 10.1007/s11912-019-0767-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
48 Fonteyne V, Ost P, Bellmunt J, Droz JP, Mongiat-Artus P, Inman B, Paillaud E, Saad F, Ploussard G. Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. Eur Urol 2018;73:40-50. [PMID: 28478043 DOI: 10.1016/j.eururo.2017.03.019] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 15.0] [Reference Citation Analysis]
49 Sprangers B, Cosmai L, Porta C. Conventional chemotherapy. Onco-Nephrology. Elsevier; 2020. pp. 127-153.e11. [DOI: 10.1016/b978-0-323-54945-5.00025-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Qian Y, Arellano J, Bhowmik D, Thomson E, Smith DM, Hechmati G, Song X. Healthcare resource use and costs associated with renal impairment in US patients with bone metastases from solid tumors. J Oncol Pharm Pract 2017;23:195-202. [DOI: 10.1177/1078155216629826] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
51 Launay-Vacher V. Cancer and the kidney: individualizing dosage according to renal function. Ann Oncol 2013;24:2713-4. [PMID: 24170609 DOI: 10.1093/annonc/mdt431] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
52 Lichtman SM, Harvey RD, Damiette Smit M, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D, Fehrenbacher L. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. JCO 2017;35:3753-9. [DOI: 10.1200/jco.2017.74.4102] [Cited by in Crossref: 78] [Cited by in F6Publishing: 37] [Article Influence: 19.5] [Reference Citation Analysis]
53 Hong J, Lee S, Chun G, Jung JY, Park J, Ahn JY, Cho EK, Shin DB, Lee JH. Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma. Blood Res 2016;51:113-21. [PMID: 27382556 DOI: 10.5045/br.2016.51.2.113] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
54 Lipton A, Balakumaran A. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors. Expert Review of Clinical Pharmacology 2014;5:359-71. [DOI: 10.1586/ecp.12.35] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
55 Xie F, Xu Y, Wang L, Mitchelson K, Xing W, Cheng J. Use of cellular electrical impedance sensing to assess in vitro cytotoxicity of anticancer drugs in a human kidney cell nephrotoxicity model. Analyst 2012;137:1343. [DOI: 10.1039/c2an16141a] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
56 Russo P. End stage and chronic kidney disease: associations with renal cancer. Front Oncol. 2012;2:28. [PMID: 22649783 DOI: 10.3389/fonc.2012.00028] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
57 Chen C, Lin J, Huang J, Chen K, Shih J, Yu C, Yang P. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2015;16:e131-40. [DOI: 10.1016/j.cllc.2015.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
58 Nagayama Y, Nakaura T, Oda S, Utsunomiya D, Funama Y, Iyama Y, Taguchi N, Namimoto T, Yuki H, Kidoh M, Hirata K, Nakagawa M, Yamashita Y. Dual-layer DECT for multiphasic hepatic CT with 50 percent iodine load: a matched-pair comparison with a 120 kVp protocol. Eur Radiol 2018;28:1719-30. [PMID: 29063254 DOI: 10.1007/s00330-017-5114-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
59 Chew-Harris JS, Florkowski CM, George PM, Endre ZH. Comparative performances of the new chronic kidney disease epidemiology equations incorporating cystatin C for use in cancer patients. Asia Pac J Clin Oncol 2015;11:142-51. [PMID: 25471594 DOI: 10.1111/ajco.12312] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
60 Kawai K, Ichioka D, Inai H, Miyazaki J, Nishiyama H. Assessment and management of renal impairment in chemotherapy for urogenital cancer. Jpn J Clin Oncol 2013;43:1055-63. [PMID: 24031085 DOI: 10.1093/jjco/hyt132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
61 Mroue A, Moujaess E, Kourie HR, Azar H, Finianos S, Chelala D. Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. Crit Rev Oncol Hematol 2021;157:103169. [PMID: 33302157 DOI: 10.1016/j.critrevonc.2020.103169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
62 den Exter PL, Kooiman J, van der Hulle T, Huisman MV. New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism. Best Practice & Research Clinical Haematology 2013;26:163-9. [DOI: 10.1016/j.beha.2013.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
63 Pontes Lde B, Antunes YP, Bugano DD, Karnakis T, Giglio AD, Kaliks RA. Prevalence of renal insufficiency in elderly cancer patients in a tertiary cancer center. Einstein (Sao Paulo) 2014;12:300-3. [PMID: 25295449 DOI: 10.1590/s1679-45082014ao3003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
64 Launay-Vacher V, Janus N, Deray G. Renal insufficiency and cancer treatments. ESMO Open 2016;1:e000091. [PMID: 27843635 DOI: 10.1136/esmoopen-2016-000091] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
65 Spazzapan S, Crivellari D, Bedard P, Lombardi D, Miolo G, Scalone S, Veronesi A. Therapeutic management of breast cancer in the elderly. Expert Opinion on Pharmacotherapy 2011;12:945-60. [DOI: 10.1517/14656566.2011.540570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
66 Kataoka S, Nishikawa Y, Funakoshi T, Horimatsu T, Kondo N, Matsubara T, Yanagita M, Matsumoto S, Muto M. Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab. Clin J Gastroenterol 2020;13:316-9. [DOI: 10.1007/s12328-019-01060-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
67 Xiao JJ, Chen JS, Lum BL, Graham RA. A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions. Anticancer Drugs 2017;28:677-701. [PMID: 28542036 DOI: 10.1097/CAD.0000000000000513] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
68 Kim H, Lee M, Cha MU, Nam KH, An SY, Park S, Jhee JH, Yun HR, Kee YK, Park JT, Yoo TH, Kang SW, Han SH. Microscopic hematuria is a risk factor of incident chronic kidney disease in the Korean general population: a community-based prospective cohort study. QJM 2018;111:389-97. [PMID: 29554373 DOI: 10.1093/qjmed/hcy054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
69 Kitchlu A, Shapiro J, Amir E, Garg AX, Kim SJ, Wald R, Harel Z. Representation of Patients With Chronic Kidney Disease in Trials of Cancer Therapy. JAMA 2018;319:2437-9. [PMID: 29922818 DOI: 10.1001/jama.2018.7260] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
70 Hadji P, Aapro M, Costa L, Gnant M. Antiresorptive treatment options and bone health in cancer patients—safety profiles and clinical considerations. Cancer Treatment Reviews 2012;38:815-24. [DOI: 10.1016/j.ctrv.2012.03.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
71 Lichtman SM, Boparai MK. Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. Curr Treat Options Oncol 2008;9:191-203. [PMID: 18663583 DOI: 10.1007/s11864-008-0060-6] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
72 Ainsworth NL, Marshall A, Hatcher H, Whitehead L, Whitfield GA, Earl HM. Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients. Ann Oncol 2012;23:1845-53. [PMID: 22104575 DOI: 10.1093/annonc/mdr539] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
73 Lichtman SM. Chemotherapy in the elderly: are their needs being met? Therapy 2009;6:893-902. [DOI: 10.2217/thy.09.72] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
74 Li Y, Chen X, Wang Y, Hu J, Xu J, Jiang W, Shen B, Teng J, Ding X. Epidemiology of acute kidney injury and associated factors among patients with malignancy: Analysis of hospital inpatient database in Shanghai, China. Journal of Onco-Nephrology 2019;3:39-48. [DOI: 10.1177/2399369319830096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
75 Kozłowska K, Kozłowski L, Małyszko J. Hypertension prevalence in early breast cancer patients undergoing primary surgery. Adv Med Sci 2019;64:32-6. [PMID: 30419489 DOI: 10.1016/j.advms.2018.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
76 Sleilalty G, El Rassy E, Assi T, Al Rassy N, Nasseh J, Rizkallah J, Finianos S, Azar H, Chelala DN, El Karak F, Kattan J, Ghosn M. Evaluation of chronic kidney disease in cancer patients: is there a preferred estimation formula? Intern Med J 2018;48:1382-8. [DOI: 10.1111/imj.13933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
77 González J, Quiroga M, Escudero-vilaplana V, Collado-borrell R, Herranz-alonso A, Sanjurjo Sáez M. Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities. Expert Opinion on Drug Safety 2018;17:553-72. [DOI: 10.1080/14740338.2018.1477937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Bukowski RM. Temsirolimus: a safety and efficacy review. Expert Opin Drug Saf 2012;11:861-79. [PMID: 22861825 DOI: 10.1517/14740338.2012.713344] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
79 Tew WP. Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer. Curr Treat Options Oncol 2013;14:1-11. [PMID: 23307065 DOI: 10.1007/s11864-012-0219-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
80 Aapro M, Saad F. Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol 2012;4:85-101. [PMID: 22496711 DOI: 10.1177/1756287212441234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
81 Isambert N, Delord JP, Tourani JM, Fumoleau P, Ravaud A, Pinel MC, Petain A, Nguyen T, Nguyen L. How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. Br J Clin Pharmacol 2014;77:498-508. [PMID: 24283925 DOI: 10.1111/bcp.12218] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
82 Alsmadi MM, Al-Daoud NM, Jaradat MM, Alzughoul SB, Abu Kwiak AD, Abu Laila SS, Abu Shameh AJ, Alhazabreh MK, Jaber SA, Abu Kassab HT. Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment. Biopharm Drug Dispos 2021;42:263-84. [PMID: 33904202 DOI: 10.1002/bdd.2282] [Reference Citation Analysis]
83 Kishimoto K, Kobayashi R, Sano H, Suzuki D, Yasuda K, Kobayashi K. Analysis of Risk Factors for Hyponatremia During or Following Chemotherapy in Children With Cancer: A Hospital-based, Retrospective Cohort Study. Journal of Pediatric Hematology/Oncology 2016;38:443-8. [DOI: 10.1097/mph.0000000000000478] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
84 King S, Forbes K, Hanks G, Ferro C, Chambers E. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 2011;25:525-52. [DOI: 10.1177/0269216311406313] [Cited by in Crossref: 114] [Cited by in F6Publishing: 71] [Article Influence: 11.4] [Reference Citation Analysis]
85 Kurita GP, Lundström S, Sjøgren P, Ekholm O, Christrup L, Davies A, Kaasa S, Klepstad P, Dale O. Renal function and symptoms/adverse effects in opioid-treated patients with cancer. Acta Anaesthesiol Scand 2015;59:1049-59. [PMID: 25943005 DOI: 10.1111/aas.12521] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
86 Carvalho TP, Trinca F, Cardoso T, Dinis R. Haemodialysed patient with lung cancer in the COVID-19 era: a clinical challenge. BMJ Case Rep 2021;14:e243462. [PMID: 34326113 DOI: 10.1136/bcr-2021-243462] [Reference Citation Analysis]
87 Grönroos MH, Jahnukainen T, Möttönen M, Perkkiö M, Irjala K, Salmi TT. Long-term follow-up of renal function after high-dose methotrexate treatment in children: Renal Function Following HD-MTX Treatment. Pediatr Blood Cancer 2008;51:535-9. [DOI: 10.1002/pbc.21650] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
88 Jennings S, de Lemos ML, Levin A, Murray N. Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin. J Oncol Pharm Pract 2010;16:113-9. [DOI: 10.1177/1078155209337663] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
89 Albiges L, Izzedine H, Ederhy S, Robert C, Gravis G, Boyle H, Scotté F, Hartl D, Escudier B. Axitinib dans le cancer du rein métastatique: actualisation des connaissances sur la prise en charge des effets secondaires. Bulletin du Cancer 2014;101:976-88. [DOI: 10.1684/bdc.2014.2042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
90 Celik E, Samanci NS, Karadag M, Demirci NS, Cikman DI, Derin S, Bedir S, Degerli E, Oruc K, Oztas NS, Demirelli FH. Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. J Oncol Pharm Pract 2021;27:1665-73. [PMID: 33040673 DOI: 10.1177/1078155220964895] [Reference Citation Analysis]
91 Azaro A, Rodón J, Machiels JP, Rottey S, Damian S, Baird R, Garcia-Corbacho J, Mathijssen RHJ, Clot PF, Wack C, Shen L, de Jonge MJA. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function. Cancer Chemother Pharmacol 2016;78:1185-97. [PMID: 27796539 DOI: 10.1007/s00280-016-3175-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
92 Kang KW, Lee SR, Kim DS, Yu ES, Sung HJ, Kim SJ, Choi CW, Park Y, Kim BS. Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma. PLoS One 2018;13:e0192656. [PMID: 29444176 DOI: 10.1371/journal.pone.0192656] [Reference Citation Analysis]
93 Gallagher DJ, Milowsky MI. Bladder Cancer. Curr Treat Options in Oncol 2009;10:205-15. [DOI: 10.1007/s11864-009-0112-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
94 Chen J, Wang X, Luo P, He Q. Effects of unidentified renal insufficiency on the safety and efficacy of chemotherapy for metastatic colorectal cancer patients: a prospective, observational study. Support Care Cancer 2015;23:1043-8. [DOI: 10.1007/s00520-014-2461-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
95 Anido-herranz U, Fernández-núñez N, Afonso-afonso J, Santomé-couto L, Medina-colmenero A, Fernández-calvo O, Lázaro-quintela M, Vázquez S. Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer. Clin Transl Oncol 2019;21:249-58. [DOI: 10.1007/s12094-018-1928-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
96 Bennis Y, Savry A, Rocca M, Gauthier-villano L, Pisano P, Pourroy B. Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow? Int J Clin Pharm 2014;36:420-9. [DOI: 10.1007/s11096-013-9912-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
97 Todd A, Nazar H, Pearson H, Andrew L, Baker L, Husband A. Inappropriate prescribing in patients accessing specialist palliative day care services. Int J Clin Pharm 2014;36:535-43. [PMID: 24659040 DOI: 10.1007/s11096-014-9932-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
98 Gupta S, Parsa V, Heilbrun LK, Smith DW, Dickow B, Heath E, Vaishampayan U. Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs 2011;22:794-800. [PMID: 21799472 DOI: 10.1097/CAD.0b013e328346af0d] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
99 Bansal AD, Leonberg-yoo A, Schell JO, Scherer JS, Jones CA. Ten Tips Nephrologists Wish the Palliative Care Team Knew About Caring for Patients with Kidney Disease. Journal of Palliative Medicine 2018;21:546-51. [DOI: 10.1089/jpm.2018.0087] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
100 Launay-vacher V, Ayllon J, Janus N, Spano J, Ray-coquard I, Gligorov J, Pourrat X, Morere J, Beuzeboc P, Deray G, Oudard S. Drug Management of Prostate Cancer: Prevalence and Consequences of Renal Insufficiency. Clinical Genitourinary Cancer 2009;7:E83-9. [DOI: 10.3816/cgc.2009.n.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
101 Brizzi MP, La Salvia A, Tampellini M, Sonetto C, Volante M, Scagliotti GV. Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review. BMC Cancer 2018;18:311. [PMID: 29558899 DOI: 10.1186/s12885-018-4205-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
102 Peng S, Shen F, Wen A, Wang L, Fan Y, Liu X, Liu H. Detecting Lifestyle Risk Factors for Chronic Kidney Disease With Comorbidities: Association Rule Mining Analysis of Web-Based Survey Data. J Med Internet Res 2019;21:e14204. [PMID: 31821152 DOI: 10.2196/14204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
103 Zhuo M, Triantafylidis LK, Li J, Paik JM. Opioid Use in the Nondialysis Chronic Kidney Disease Population. Semin Nephrol 2021;41:33-41. [PMID: 33896472 DOI: 10.1016/j.semnephrol.2021.02.004] [Reference Citation Analysis]
104 Launay-vacher V, Etessami R, Janus N, Spano J, Ray-coquard I, Oudard S, Gligorov J, Pourrat X, Beuzeboc P, Deray G, Morere J; The Renal Insufficiency Anticancer Medications (IRMA) Study Group. Lung Cancer and Renal Insufficiency: Prevalence and Anticancer Drug Issues. Lung 2009;187:69-74. [DOI: 10.1007/s00408-008-9123-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
105 Ruiz-Argüelles A, Gastélum-Cano JM, Méndez-Huerta MA, Rodríguez-Gallegos AB, Ruiz-Argüelles GJ. Glomerular Filtration Rate in Patients with Multiple Sclerosis Undergoing Stem Cell Transplantation and Treated with Cyclophosphamide. Lab Med 2019;50:42-6. [PMID: 29917152 DOI: 10.1093/labmed/lmy028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
106 Marcolino MS, Boersma E, Clementino NC, Macedo AV, Marx-Neto AD, Silva MH, van Gelder T, Akkerhuis KM, Ribeiro AL. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol. 2011;22:2073-2079. [PMID: 21310760 DOI: 10.1093/annonc/mdq715] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
107 Becattini C, Di Nisio M, Franco L, Lee A, Agnelli G, Mandalà M. Treatment of venous thromboembolism in cancer patients: The dark side of the moon. Cancer Treat Rev 2021;96:102190. [PMID: 33812338 DOI: 10.1016/j.ctrv.2021.102190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Małyszko J, Kozlowski L, Kozłowska K, Małyszko M, Małyszko J. Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine? Oncotarget 2017;8:66601-19. [PMID: 29029541 DOI: 10.18632/oncotarget.18094] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
109 Launay-vacher V, Zimner-rapuch S, Moranne O. Évaluation de la fonction rénale chez le patient atteint de cancer. Bulletin du Cancer 2012;99:277-83. [DOI: 10.1684/bdc.2011.1485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Janus N, Launay-Vacher V, Ferrero JM, Thariat J. [Risk of cancer in patients following chronic dialysis and kidney graft]. Bull Cancer 2012;99:285-93. [PMID: 22381360 DOI: 10.1684/bdc.2012.1545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
111 Crandell BC, Bates JS, Grgic T. Start using a checklist, PRONTO: Recommendation for a standard review process for chemotherapy orders. J Oncol Pharm Pract 2018;24:609-16. [DOI: 10.1177/1078155217722594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
112 Spehlmann M, Frey N, Müller OJ. Prevention and treatment of venous thromboembolism in cancer patients. Herz 2020;45:652-8. [DOI: 10.1007/s00059-020-04961-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
113 Peyrade F, Cupissol D, Geoffrois L, Rolland F, Borel C, Ciais C, Faivre S, Guigay J. Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes. Oral Oncol 2013;49:482-91. [PMID: 23415727 DOI: 10.1016/j.oraloncology.2013.01.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
114 Wang E, Paulus JK, Hackenyos D, Inker LA, Levey AS, Mathew P. Imprecise Kidney Function Thresholds in Cancer Clinical Trials and the Potential for Harm. JNCI Cancer Spectr 2018;2:pky060. [PMID: 31360878 DOI: 10.1093/jncics/pky060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, Wynendaele W, Canon JL, Lybaert W, Nortier J. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103:1815-1821. [PMID: 21063408 DOI: 10.1038/sj.bjc.6605979] [Cited by in Crossref: 97] [Cited by in F6Publishing: 80] [Article Influence: 8.8] [Reference Citation Analysis]
116 Dooley MJ, Poole SG, Rischin D. Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose. Ann Oncol 2013;24:2746-52. [PMID: 23928359 DOI: 10.1093/annonc/mdt300] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
117 Kenzik KM, Williams GR, Bhakta N, Robison LL, Landier W, Goyal G, Mehta A, Bhatia S. Healthcare utilization and spending among older patients diagnosed with Non-Hodgkin lymphoma. J Geriatr Oncol 2021:S1879-4068(21)00140-5. [PMID: 34176753 DOI: 10.1016/j.jgo.2021.06.006] [Reference Citation Analysis]
118 Arita M, Watanabe S, Aoki N, Kuwahara S, Suzuki R, Goto S, Abe Y, Takahashi M, Sato M, Hokari S, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Hayashi M, Ohshima Y, Kabasawa H, Hosojima M, Koya T, Saito A, Kikuchi T. Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity. Sci Rep 2021;11:750. [PMID: 33437029 DOI: 10.1038/s41598-020-80853-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
119 Shahinian VB, Bahl A, Niepel D, Lorusso V. Considering renal risk while managing cancer. Cancer Manag Res 2017;9:167-78. [PMID: 28553142 DOI: 10.2147/CMAR.S125864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
120 Gatti M, Raschi E, Poluzzi E, Martignani C, Salvagni S, Ardizzoni A, Diemberger I. The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. Curr Heart Fail Rep 2020;17:365-83. [PMID: 33025463 DOI: 10.1007/s11897-020-00485-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
121 Desai SH, Al-Shbool G, Desale S, Veis J, Malkovska V. Lymphoma survivors have an increased long-term risk of chronic kidney disease. Leuk Lymphoma 2020;61:2923-30. [PMID: 32654590 DOI: 10.1080/10428194.2020.1786555] [Reference Citation Analysis]
122 Janus N, Launay-Vacher V, Deray G, Islam MS, Thyss A, Thariat J. [Management of targeted therapies in hemodialysis patients]. Bull Cancer 2012;99:381-8. [PMID: 22133789 DOI: 10.1684/bdc.2011.1484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
123 Lichtman SM, Cirrincione CT, Hurria A, Jatoi A, Theodoulou M, Wolff AC, Gralow J, Morganstern DE, Magrinat G, Cohen HJ, Muss HB. Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. J Clin Oncol 2016;34:699-705. [PMID: 26755510 DOI: 10.1200/JCO.2015.62.6341] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
124 Ng T, Chan A. Dosing modifications of targeted cancer therapies in patients with special needs: evidence and controversies. Crit Rev Oncol Hematol 2012;81:58-74. [PMID: 21429761 DOI: 10.1016/j.critrevonc.2011.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
125 Spanakis M, Marias K. In silico evaluation of gadofosveset pharmacokinetics in different population groups using the Simcyp® simulator platform. In Silico Pharmacol 2014;2:2. [PMID: 27502621 DOI: 10.1186/s40203-014-0002-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
126 Ording AG, Garne JP, Nyström PM, Frøslev T, Sørensen HT, Lash TL. Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis--a Danish nationwide matched cohort study. PLoS One 2013;8:e76013. [PMID: 24130755 DOI: 10.1371/journal.pone.0076013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
127 Bednarek A, Mykała-Cieśla J, Pogoda K, Jagiełło-Gruszfeld A, Kunkiel M, Winder M, Chudek J. Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease. J Oncol 2020;2020:7267083. [PMID: 32508921 DOI: 10.1155/2020/7267083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
128 Silvestris N, Argentiero A, Cosmai L, Porta C, Gesualdo L, Brunori G, Brunetti O, Rampino T, Secondino S, Rizzo G, Pedrazzoli P. Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology 2019;140:39-51. [DOI: 10.1016/j.critrevonc.2019.05.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
129 Capasso A, Benigni A, Capitanio U, Danesh FR, Di Marzo V, Gesualdo L, Grandaliano G, Jaimes EA, Malyszko J, Perazella MA, Qian Q, Ronco P, Rosner MH, Trepiccione F, Viggiano D, Zoccali C, Capasso G, Akitaka A, Alahoti A, Alexander TR, Altucci L, Amer H, Barone V, Benigni A, Biancone L, Bonventre JV, Camussi G, Capasso A, Ciardiello F, Capitanio U, Caraglia M, Cartenì G, Cervantes A, Citterio F, Cosmai L, Danesh FR, Daniele B, D’errico A, De Vita F, Di Marzo V, Ereditato A, Falco G, Fouque D, Franco R, Gallieni M, Gambaro G, Gesualdo L, Grandaliano G, Kuo C, Jaimes EA, Launay-vacher V, Maiello E, Mallamaci F, Malysxko J, Marino G, Martinelli E, Matarese G, Matsubara T, Messa P, Messina C, Mirone V, Morgillo F, Costa AN, Orditura M, Pani A, Perazella MA, Perna A, Pisano C, Pitts T, Porta C, Procopio G, Qian Q, Remuzzi G, Ronco P, Rosner MH, Russo D, Siu LL, Stadler W, Trepiccione F, Troiani T, Viggiano D, Weisz A, Więcek A, Xiaoqiang D, Zecchino O, Zoccali C. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney International 2019;96:555-67. [DOI: 10.1016/j.kint.2019.04.043] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]
130 Launay-Vacher V, Aapro M, De Castro G Jr, Cohen E, Deray G, Dooley M, Humphreys B, Lichtman S, Rey J, Scotté F, Wildiers H, Sprangers B. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 2015;26:1677-84. [PMID: 25735315 DOI: 10.1093/annonc/mdv136] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
131 Graciano vera N, Pino villarreal L, Ureña vargas J. Carboplatin Dosing Accuracy by Estimation of Glomerular Filtration versus Creatinuria in Cancer Patients. Chemotherapy 2018;63:137-42. [DOI: 10.1159/000488538] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Umakanthan JM, Lunning MA. Management of untreated advanced stage follicular lymphoma: Role of patient discernment. Best Pract Res Clin Haematol 2018;31:23-30. [PMID: 29452663 DOI: 10.1016/j.beha.2017.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, Swan SK, Lunde NM, Bello CL. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010;50:472-81. [PMID: 19779038 DOI: 10.1177/0091270009347868] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
134 Levy A, Albiges-sauvin L, Massard C, Izzedine H, Edhery S, Bahleda R, Gomez-roca C, Chargari C, Brocheriou-spelle I, Soria J. Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Invest New Drugs 2012;30:1116-20. [DOI: 10.1007/s10637-011-9671-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
135 Abdelrahim M, Abudayyeh A. Renal Toxicity. Adv Exp Med Biol 2020;1244:287-93. [PMID: 32301023 DOI: 10.1007/978-3-030-41008-7_16] [Reference Citation Analysis]
136 Quiroga García V, Cirauqui Cirauqui B, Tobey Robaina L, López Sisamon D, Hardy-Werbin M, Blanca AB, Margelí Vila M. Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report. Anticancer Drugs 2016;27:464-9. [PMID: 26813866 DOI: 10.1097/CAD.0000000000000339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
137 Roza T, Hakim L, van Poppel H, Joniau S. Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions. Drugs Aging. 2013;30:877-886. [PMID: 24072355 DOI: 10.1007/s40266-013-0117-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
138 Sato K, Watanabe S, Ohtsubo A, Shoji S, Ishikawa D, Tanaka T, Nozaki K, Kondo R, Okajima M, Miura S, Tanaka J, Sakagami T, Koya T, Kagamu H, Yoshizawa H, Narita I. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer 2016;16:222. [PMID: 26979596 DOI: 10.1186/s12885-016-2271-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
139 Werner S, Bez C, Hinterleitner C, Horger M. Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol. PLoS One 2020;15:e0233433. [PMID: 32437415 DOI: 10.1371/journal.pone.0233433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
140 Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082-3092. [PMID: 22975218 DOI: 10.1016/j.ejca.2012.08.002] [Cited by in Crossref: 357] [Cited by in F6Publishing: 292] [Article Influence: 39.7] [Reference Citation Analysis]
141 Ording AG, Horváth-Puhó E, Lash TL, Ehrenstein V, Borre M, Vyberg M, Sørensen HT. Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995-2011. Acta Oncol 2016;55:611-8. [PMID: 26586474 DOI: 10.3109/0284186X.2015.1105382] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
142 Launay-Vacher V, Gligorov J, Le Tourneau C, Janus N, Spano JP, Ray-Coquard I, Oudard S, Pourrat X, Morere JF, Deray G, Beuzeboc P; Renal Insufficiency and Anticancer Medications (IRMA) Study Group. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 2010;124:745-53. [PMID: 18704681 DOI: 10.1007/s10549-008-0131-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
143 Lotan E, Leader A, Lishner M, Gottfried M, Pereg D. Unrecognized renal insufficiency and chemotherapy-associated adverse effects among breast cancer patients. Anticancer Drugs 2012;23:991-5. [PMID: 22728764 DOI: 10.1097/CAD.0b013e328355dd8a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
144 Liu W, Peng JF, Tang MJ. Individualized Treatment Analysis Of Breast Cancer With Chronic Renal Failure. Onco Targets Ther. 2019;12:7767-7772. [PMID: 31571926 DOI: 10.2147/ott.s223729] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Sprangers B, Abudayyeh A, Latcha S, Perazella MA, Jhaveri KD. How to determine kidney function in cancer patients? Eur J Cancer 2020;132:141-9. [PMID: 32361629 DOI: 10.1016/j.ejca.2020.03.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
146 Deak AT, Troppan K, Rosenkranz AR. Anemia management in cancer patients with chronic kidney disease. European Journal of Internal Medicine 2016;36:13-9. [DOI: 10.1016/j.ejim.2016.08.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
147 Launay-Vacher V, Ayllon J, Janus N, Medioni J, Deray G, Isnard-Bagnis C, Oudard S. Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. Urol Oncol 2011;29:492-4. [PMID: 19914102 DOI: 10.1016/j.urolonc.2009.07.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
148 Troxell ML, Higgins JP, Kambham N. Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies. Adv Anat Pathol 2016;23:310-29. [PMID: 27403615 DOI: 10.1097/PAP.0000000000000122] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
149 Franken LG, Masman AD, de Winter BC, Koch BC, Baar FP, Tibboel D, van Gelder T, Mathot RA. Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients. Clin Pharmacokinet 2016;55:697-709. [PMID: 26715216 DOI: 10.1007/s40262-015-0345-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
150 César BN, Durão Júnior MS. Acute kidney injury in cancer patients. Rev Assoc Med Bras (1992) 2020;66Suppl 1:s25-30. [PMID: 31939532 DOI: 10.1590/1806-9282.66.S1.25] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
151 Akinbolade O, Husband A, Forrest S, Todd A. Deprescribing in advanced illness. Progress in Palliative Care 2016;24:268-71. [DOI: 10.1080/09699260.2016.1192321] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
152 Deskur-Smielecka E, Kotlinska-Lemieszek A, Chudek J, Wieczorowska-Tobis K. Assessment of renal function in geriatric palliative care patients - comparison of creatinine-based estimation equations. Clin Interv Aging 2017;12:977-83. [PMID: 28694691 DOI: 10.2147/CIA.S130583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
153 Bergmann L, Maute L, Guschmann M. Temsirolimus for advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2014;14:9-21. [PMID: 24313573 DOI: 10.1586/14737140.2014.864562] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
154 Rassy EE, Kourie HR, Rizkallah J, Karak FE, Hanna C, Chelala DN, Ghosn M. Immune checkpoint inhibitors renal side effects and management. Immunotherapy 2016;8:1417-25. [PMID: 28000536 DOI: 10.2217/imt-2016-0099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
155 Syrios J, Kechagias G, Tsavaris N. Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review. BMC Nephrol 2013;14:84. [PMID: 23587009 DOI: 10.1186/1471-2369-14-84] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
156 Hong SI, Ahn S, Lee YS, Kim WY, Lim KS, Lee JH, Lee JL. Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography. Support Care Cancer 2016;24:1011-7. [PMID: 26238629 DOI: 10.1007/s00520-015-2875-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
157 González Cervantes JJ, Mascarós Martínez JM, Arana E. Administration of iodinated contrast: What is the risk in cancer patients? Eur J Cancer Care (Engl) 2021;30:e13351. [PMID: 33135211 DOI: 10.1111/ecc.13351] [Reference Citation Analysis]
158 Al-Mansour Z, Pang L, Bathini V. Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient? Drugs Aging 2019;36:1-11. [PMID: 30478744 DOI: 10.1007/s40266-018-0619-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
159 Ahmad A, Shi J, Ansari S, Afaghani J, Molina J, Pollack A, Merscher S, Zeidan YH, Fornoni A, Marples B. Noninvasive assessment of radiation-induced renal injury in mice. Int J Radiat Biol 2021;97:664-74. [PMID: 33464992 DOI: 10.1080/09553002.2021.1876950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Malyszko J, Lee MW, Capasso G, Kulicki P, Matuszkiewicz-rowinska J, Ronco P, Stevens P, Tesarova P, Viggiano D, Capasso A. How to assess kidney function in oncology patients. Kidney International 2020;97:894-903. [DOI: 10.1016/j.kint.2019.12.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
161 Jagieła J, Bartnicki P, Rysz J. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. Int J Mol Sci 2021;22:4618. [PMID: 33924827 DOI: 10.3390/ijms22094618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Barraclough LH, Field C, Wieringa G, Swindell R, Livsey JE, Davidson SE. Estimation of renal function -- what is appropriate in cancer patients? Clin Oncol (R Coll Radiol) 2008;20:721-6. [PMID: 18995170 DOI: 10.1016/j.clon.2008.09.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
163 Skinner R. Nephrotoxicity of cancer treatment in children. Pediatric Health 2010;4:519-38. [DOI: 10.2217/phe.10.60] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
164 Franken LG, de Winter BC, van Esch HJ, van Zuylen L, Baar FP, Tibboel D, Mathôt RA, van Gelder T, Koch BC. Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol. Expert Opin Drug Metab Toxicol 2016;12:669-80. [PMID: 27081769 DOI: 10.1080/17425255.2016.1179281] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
165 Porta C, Bamias A, Danesh FR, Dębska-Ślizień A, Gallieni M, Gertz MA, Kielstein JT, Tesarova P, Wong G, Cheung M, Wheeler DC, Winkelmayer WC, Małyszko J; Conference Participants. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney Int 2020;98:1108-19. [PMID: 33126977 DOI: 10.1016/j.kint.2020.06.046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
166 Bunel V, Tournay Y, Baudoux T, De Prez E, Marchand M, Mekinda Z, Maréchal R, Roumeguère T, Antoine MH, Nortier JL. Early detection of acute cisplatin nephrotoxicity: interest of urinary monitoring of proximal tubular biomarkers. Clin Kidney J 2017;10:639-47. [PMID: 28979774 DOI: 10.1093/ckj/sfx007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
167 Ren J, Huo Z, Wang X, Liu Y, Yang G. Serial renography for evaluation of the impact of capecitabine therapy on renal function: A case report. Medicine (Baltimore) 2017;96:e6861. [PMID: 28562534 DOI: 10.1097/MD.0000000000006861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
168 Ho CC, Wen PC, Yu WC, Hu YW, Yang CC. Pre-existing Chronic Kidney Disease and Hypertension Increased the Risk of Cardiotoxicity among Colorectal Cancer Patients Treated with Anti-Cancer Drugs. J Chin Med Assoc 2021. [PMID: 34320515 DOI: 10.1097/JCMA.0000000000000590] [Reference Citation Analysis]
169 Abudayyeh A, Song J, Abdelrahim M, Dahbour I, Page VD, Zhou S, Shen C, Zhao B, Pai RN, Amaram-Davila J, Manzano JG, George MC, Yennu S, Mandayam SA, Nates JL, Moss AH. Renal Replacement Therapy in Patients With Stage IV Cancer Admitted to the Intensive Care Unit With Acute Kidney Injury at a Comprehensive Cancer Center Was Not Associated With Survival. Am J Hosp Palliat Care 2020;37:707-15. [PMID: 31986903 DOI: 10.1177/1049909120902115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
170 Launay-vacher V. Epidemiology of Chronic Kidney Disease in Cancer Patients: Lessons From the IRMA Study Group. Seminars in Nephrology 2010;30:548-56. [DOI: 10.1016/j.semnephrol.2010.09.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
171 Olsson AK, Cedervall J. NETosis in Cancer - Platelet-Neutrophil Crosstalk Promotes Tumor-Associated Pathology. Front Immunol 2016;7:373. [PMID: 27708646 DOI: 10.3389/fimmu.2016.00373] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
172 Fuentes HE, Tafur AJ, Caprini JA. Cancer-associated thrombosis. Disease-a-Month 2016;62:121-58. [DOI: 10.1016/j.disamonth.2016.03.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
173 Aapro M, Launay-vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treatment Reviews 2012;38:235-40. [DOI: 10.1016/j.ctrv.2011.05.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
174 Chang FC, Chen TW, Huang TT, Lin WC, Liu JS, Chiang WC, Chen YM, Hsu C, Yeh KH, Chu TS. Spectrum of cancer patients receiving renal biopsy. J Formos Med Assoc 2021:S0929-6646(21)00073-5. [PMID: 33640191 DOI: 10.1016/j.jfma.2021.02.009] [Reference Citation Analysis]
175 Porta C, Cosmai L, Gallieni M, Perazella MA. Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. JCO 2016;34:2429-30. [DOI: 10.1200/jco.2016.67.0786] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
176 Haumann J, Joosten E(A, Everdingen MHVDB. Pain prevalence in cancer patients: status quo or opportunities for improvement? Current Opinion in Supportive & Palliative Care 2017;11:99-104. [DOI: 10.1097/spc.0000000000000261] [Cited by in Crossref: 33] [Cited by in F6Publishing: 5] [Article Influence: 8.3] [Reference Citation Analysis]
177 Königsbrügge O, Lötsch F, Zielinski C, Pabinger I, Ay C. Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. Thromb Res 2014;134:44-9. [PMID: 24792954 DOI: 10.1016/j.thromres.2014.04.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
178 Saeheng T, Na-Bangchang K, Karbwang J. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review. Eur J Clin Pharmacol 2018;74:1365-76. [PMID: 29978293 DOI: 10.1007/s00228-018-2513-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
179 Saif MW, Becerra CR, Fakih MG, Sun W, Popovic L, Krishnamurthi S, George TJ, Rudek MA, Shepard DR, Skopek J, Sramek V, Zaric B, Yamamiya I, Benhadji KA, Hamada K, He Y, Rosen L. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemother Pharmacol 2021;88:485-97. [PMID: 34097100 DOI: 10.1007/s00280-021-04308-z] [Reference Citation Analysis]
180 Tew WP, Lichtman SM. Ovarian Cancer in Older Women. Seminars in Oncology 2008;35:582-9. [DOI: 10.1053/j.seminoncol.2008.08.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
181 Eppenga WL, Kramers C, Derijks HJ, Wensing M, Wetzels JF, De Smet PA. Individualizing pharmacotherapy in patients with renal impairment: the validity of the Modification of Diet in Renal Disease formula in specific patient populations with a glomerular filtration rate below 60 ml/min. A systematic review. PLoS One 2015;10:e0116403. [PMID: 25741695 DOI: 10.1371/journal.pone.0116403] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
182 Johansen KB, Balchen T. Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance? Exp Hematol Oncol 2013;2:21. [PMID: 23927414 DOI: 10.1186/2162-3619-2-21] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
183 Kemlin D, Biard L, Kerhuel L, Zafrani L, Venot M, Teixeira L, Schlemmer B, Azoulay E, Canet E. Acute kidney injury in critically ill patients with solid tumours. Nephrol Dial Transplant 2018;33:1997-2005. [PMID: 29579262 DOI: 10.1093/ndt/gfy051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
184 Jaggers JL, Giri S, Klepin HD, Wildes TM, Olin RL, Artz A, Wall S, Jaglowski S, William B, Benson DM, Rosko AE. Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. J Geriatr Oncol 2021;12:235-8. [PMID: 32855108 DOI: 10.1016/j.jgo.2020.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Guddati AK, Joy PS, Marak CP. Dose adjustment of carboplatin in patients on hemodialysis. Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0848-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
186 Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Renal effects of targeted anticancer therapies. Nat Rev Nephrol 2015;11:354-70. [PMID: 25734768 DOI: 10.1038/nrneph.2015.15] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 10.2] [Reference Citation Analysis]
187 Sculier J, Botta I, Bucalau A, Compagnie M, Eskenazi A, Fischler R, Gorham J, Mans L, Rozen L, Speybrouck S, Wang X, Meert A, Berghmans T. Medical anticancer treatment of lung cancer associated with comorbidities: A review. Lung Cancer 2015;87:241-8. [DOI: 10.1016/j.lungcan.2015.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
188 Meghani SH, Rosa WE, Chittams J, Vallerand AH, Bao T, Mao JJ. Both Race and Insurance Type Independently Predict the Selection of Oral Opioids Prescribed to Cancer Outpatients. Pain Manag Nurs 2020;21:65-71. [PMID: 31501079 DOI: 10.1016/j.pmn.2019.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
189 Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY. A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos. 2013;34:141-154. [PMID: 23225350 DOI: 10.1002/bdd.1830] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 7.4] [Reference Citation Analysis]
190 Lheureux S, Clarisse B, Launay-Vacher V, Gunzer K, Delcambre-Lair C, Bouhier-Leporrier K, Kaluzinski L, Maron D, Ngo MD, Grossi S, Dubois B, Zalcman G, Joly F. Evaluation of current practice: management of chemotherapy-related toxicities. Anticancer Drugs 2011;22:919-25. [PMID: 21795972 DOI: 10.1097/CAD.0b013e328349d7f1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
191 Kirschner M, do Ó Hartmann N, Parmentier S, Hart C, Henze L, Bisping G, Griesshammer M, Langer F, Pabinger-Fasching I, Matzdorff A, Riess H, Koschmieder S. Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO). Cancers (Basel) 2021;13:2905. [PMID: 34200741 DOI: 10.3390/cancers13122905] [Reference Citation Analysis]
192 Currow DC, Phillips JL. Chronic Conditions and Cancer at the End of Life. In: Koczwara B, editor. Cancer and Chronic Conditions. Singapore: Springer; 2016. pp. 455-75. [DOI: 10.1007/978-981-10-1844-2_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
193 Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21:1395-1403. [PMID: 20118214 DOI: 10.1093/annonc/mdp598] [Cited by in Crossref: 102] [Cited by in F6Publishing: 70] [Article Influence: 9.3] [Reference Citation Analysis]
194 Holweger K, Lipp H, Beijnen JH, Bokemeyer C, Hartmann JT. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin. Cancer Chemother Pharmacol 2011;68:693-701. [DOI: 10.1007/s00280-010-1537-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
195 Casal MA, Nolin TD, Beumer JH. Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing. Clin J Am Soc Nephrol 2019;14:587-95. [PMID: 30890575 DOI: 10.2215/CJN.11721018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 8.5] [Reference Citation Analysis]
196 Martinez-Erro S, Navas F, Romaní-Cubells E, Fernández-García P, Morales V, Sanz R, García-Muñoz RA. Kidney-Protector Lipidic Cilastatin Derivatives as Structure-Directing Agents for the Synthesis of Mesoporous Silica Nanoparticles for Drug Delivery. Int J Mol Sci 2021;22:7968. [PMID: 34360733 DOI: 10.3390/ijms22157968] [Reference Citation Analysis]
197 Alonso F, Auñón P, Cavero T, Salgueira M, Praga M, Quiroga B, de Francisco ÁLM, Macía M; Grupo Español de Onconefrología (ONCONEFRO). Monographic consultation of onconephrology. Rationale and implementation. Nefrologia 2021;41:154-64. [PMID: 34167768 DOI: 10.1016/j.nefroe.2021.04.006] [Reference Citation Analysis]
198 Casal MA, Ivy SP, Beumer JH, Nolin TD. Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants. Lancet Oncol 2021;22:1333-40. [PMID: 34399096 DOI: 10.1016/S1470-2045(21)00377-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Torres da Costa E Silva V, Costalonga EC, Coelho FO, Caires RA, Burdmann EA. Assessment of Kidney Function in Patients With Cancer. Adv Chronic Kidney Dis 2018;25:49-56. [PMID: 29499887 DOI: 10.1053/j.ackd.2017.10.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
200 Kitchlu A, Chan CT, Leung N, Chen S, Latcha S, Tam P. Perspectives From an Onconephrology Interest Group: Conference Report. Can J Kidney Health Dis 2020;7:2054358120962589. [PMID: 33117547 DOI: 10.1177/2054358120962589] [Reference Citation Analysis]
201 Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, van Herpen CML, van Erp NP. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol 2019;20:e200-7. [PMID: 30942181 DOI: 10.1016/S1470-2045(19)30145-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 22.0] [Reference Citation Analysis]
202 Janus N, Launay-Vacher V, Deray G, Thyss A, Thariat J. [Management of chemotherapy in hemodialysis patients]. Bull Cancer 2012;99:371-80. [PMID: 22133734 DOI: 10.1684/bdc.2011.1483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
203 Mendes MS, Hatley O, Gill KL, Yeo KR, Ke AB. A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients. Eur J Pharm Sci 2020;150:105355. [PMID: 32438273 DOI: 10.1016/j.ejps.2020.105355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
204 Chancharoenthana W, Wattanatorn S, Vadcharavivad S, Eiam-Ong S, Leelahavanichkul A. Agreement and Precision Analyses of Various Estimated Glomerular Filtration Rate Formulae in Cancer Patients. Sci Rep 2019;9:19356. [PMID: 31852941 DOI: 10.1038/s41598-019-55833-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
205 Miller KD, Pandey M, Jain R, Mehta R. Cancer Survivorship and Models of Survivorship Care: A Review. Am J Clin Oncol 2015;38:627-33. [PMID: 25635609 DOI: 10.1097/COC.0000000000000153] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
206 Cao J, Zhao X, Zhong Z, Zhang L, Zhu X, Xu R. Prognostic Value of Pre-operative Renal Insufficiency in Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Sci Rep 2016;6:35214. [PMID: 27725745 DOI: 10.1038/srep35214] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
207 Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA Cancer J Clin 2021;71:47-77. [PMID: 32853404 DOI: 10.3322/caac.21636] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
208 Barai S, Gambhir S, Jain S, Rastogi N. Evaluation of Basal Renal Function in Treatment-naïve Patients with Malignancy and Comparison with Age Matched Healthy Control. World J Nucl Med 2016;15:148-52. [PMID: 27651734 DOI: 10.4103/1450-1147.167602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
209 Lee KA, Ganta N, Horton JR, Chai E. Evidence for Neurotoxicity Due to Morphine or Hydromorphone Use in Renal Impairment: A Systematic Review. J Palliat Med 2016;19:1179-87. [PMID: 27399959 DOI: 10.1089/jpm.2016.0101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
210 Skinner R, Kaplan R, Nathan PC. Renal and Pulmonary Late Effects of Cancer Therapy. Seminars in Oncology 2013;40:757-73. [DOI: 10.1053/j.seminoncol.2013.09.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
211 Niscola P, Vischini G, Tendas A, Scaramucci L, Giovannini M, Bondanini F, Romani C, Brunetti GA, Cartoni C, Cupelli L, Ferrannini M, Perrotti A, Del Poeta G, Palumbo R, de Fabritiis P. Management of hematological malignancies in patients affected by renal failure. Expert Rev Anticancer Ther 2011;11:415-32. [PMID: 21417855 DOI: 10.1586/era.11.2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
212 Cedervall J, Dragomir A, Saupe F, Zhang Y, Ärnlöv J, Larsson E, Dimberg A, Larsson A, Olsson AK. Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice. Oncoimmunology 2017;6:e1320009. [PMID: 28919990 DOI: 10.1080/2162402X.2017.1320009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
213 Peterson LL, Hurria A, Feng T, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Glezerman I, Katheria V, Zavala L, Smith DD, Sun CL, Tew WP. Association between renal function and chemotherapy-related toxicity in older adults with cancer. J Geriatr Oncol 2017;8:96-101. [PMID: 27856262 DOI: 10.1016/j.jgo.2016.10.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
214 Tourette-Turgis C, Isnard-Bagnis C. [Patient education]. Nephrol Ther 2013;9:235-40. [PMID: 23582652 DOI: 10.1016/j.nephro.2013.02.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
215 Westphalen CB, Kruger S, Haas M, Heinemann V, Boeck S. Safety of palliative chemotherapy in advanced pancreatic cancer. Expert Opin Drug Saf 2016;15:947-54. [PMID: 27070177 DOI: 10.1080/14740338.2016.1177510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
216 Rajiah P, Ciancibello L, Novak R, Sposato J, Landeras L, Gilkeson R. Ultra-low dose contrast CT pulmonary angiography in oncology patients using a high-pitch helical dual-source technology. Diagn Interv Radiol 2019;25:195-203. [PMID: 31063136 DOI: 10.5152/dir.2019.17498] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]